文献速递泌尿生殖介入CTMRPET

寡进展转移性去势抵抗性前列腺癌放疗的多中心分析

Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis.
PubMed 文献 · Radiol Med · 2021-11-08

PDT后1年无下一代系统治疗生存率、影像无进展生存率和总生存率分别为49.8%、50.4%和82.1%,仅1例出现晚期≥2级毒性。多因素分析显示初诊mHSPC时多转移状态和mCRPC诊断时PSA倍增时间与NEST-free生存及r-PFS相关。

要点

  • 寡进展mCRPC患者接受放疗可延长ARDT疗效并延迟系统治疗转换。
  • 初诊mHSPC时多转移状态和mCRPC时PSA倍增时间短提示预后较差。
  • 放疗安全性良好,晚期≥2级毒性发生率低。

局限性

  • 回顾性研究设计
  • 需要前瞻性试验验证

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To retrospectively estimate the impact of radiotherapy as a progression-directed therapy (PDT) in oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) patients under androgen receptor-target therapy (ARTT).

MATERIALS AND METHODS: mCRPC patients are treated with PDT. End-points were time to next-line systemic treatment (NEST), radiological progression-free survival (r-PFS) and overall survival (OS). Toxicity was registered according to Common Terminology Criteria for Adverse Events v4.0. Survival analysis was performed using the Kaplan-Meier method; univariate and multivariate analyses were performed.

RESULTS: Fifty-seven patients were analyzed. The median follow-up after PDT was 25.2 months (interquartile, 17.1-44.5). One-year NEST-free survival, r-PFS and OS were 49.8%, 50.4% and 82.1%, respectively. At multivariate analysis, polymetastatic condition at diagnosis of metastatic hormone-sensitive prostate cancer (mHSPC) (HR 2.82, p = 0.004) and PSA doubling time at diagnosis of mCRPC (HR 2.76, p = 0.006) were associated with NEST-free survival. The same variables were associated with r-PFS (HR 2.32, p = 0.021; HR 2.24, p = 0.021). One patient developed late grade ≥ 2 toxicity.

CONCLUSION: Our study shows that radiotherapy in oligoprogressive mCRPC is safe, is effective and seems to prolong the efficacy of ARTT in patients who otherwise would have gone systemic treatment switch, positively affecting disease progression. Prospective trials are needed.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Valeriani, Detti, Fodor, et al. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis. Radiol Med. 2021. PMID: 34748151. doi:10.1007/s11547-021-01424-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。